WO2001089584A3 - Contrast agents - Google Patents

Contrast agents Download PDF

Info

Publication number
WO2001089584A3
WO2001089584A3 PCT/NO2001/000215 NO0100215W WO0189584A3 WO 2001089584 A3 WO2001089584 A3 WO 2001089584A3 NO 0100215 W NO0100215 W NO 0100215W WO 0189584 A3 WO0189584 A3 WO 0189584A3
Authority
WO
WIPO (PCT)
Prior art keywords
contrast agents
contrast
contrast agent
activity
normal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NO2001/000215
Other languages
French (fr)
Other versions
WO2001089584A2 (en
Inventor
Jo Klaveness
Helge Tolleshaug
Alan Cuthbertson
Mari Ann Kulseth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
Amersham Health AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NO20002644A external-priority patent/NO20002644D0/en
Application filed by Amersham Health AS filed Critical Amersham Health AS
Priority to JP2001585825A priority Critical patent/JP2003534297A/en
Priority to AU2001274683A priority patent/AU2001274683A1/en
Priority to EP01941323A priority patent/EP1283728A2/en
Publication of WO2001089584A2 publication Critical patent/WO2001089584A2/en
Publication of WO2001089584A3 publication Critical patent/WO2001089584A3/en
Priority to US10/302,419 priority patent/US20030170173A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasonic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acoustics & Sound (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

This invention relates to contrast agents and the use of these contrast agents for diagnosis of diseases in humans and animals based on mapping of metabolic activity. The contrast agents can be used to identify tissue or cells with metabolic activity or enzymatic activity deviating from the normal. A contrast agent substrate changes pharmacodynamic and/or pharmacokinetic properties upon a chemical modification from a contrast agent substrate to a contrast agent product in a specific enzymatic transformation, thereby detecting areas of disease upon a deviation in the enzyme activity from the normal.
PCT/NO2001/000215 2000-05-23 2001-05-23 Contrast agents Ceased WO2001089584A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001585825A JP2003534297A (en) 2000-05-23 2001-05-23 Contrast agent
AU2001274683A AU2001274683A1 (en) 2000-05-23 2001-05-23 Contrast agents
EP01941323A EP1283728A2 (en) 2000-05-23 2001-05-23 Contrast agents
US10/302,419 US20030170173A1 (en) 2000-05-23 2002-11-22 Contrast agents

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO20002644 2000-05-23
NO20002644A NO20002644D0 (en) 2000-05-23 2000-05-23 Imaging agents
US21006100P 2000-06-07 2000-06-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/302,419 Continuation US20030170173A1 (en) 2000-05-23 2002-11-22 Contrast agents

Publications (2)

Publication Number Publication Date
WO2001089584A2 WO2001089584A2 (en) 2001-11-29
WO2001089584A3 true WO2001089584A3 (en) 2002-05-02

Family

ID=26649235

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NO2001/000215 Ceased WO2001089584A2 (en) 2000-05-23 2001-05-23 Contrast agents

Country Status (3)

Country Link
US (1) US20030170173A1 (en)
EP (1) EP1283728A2 (en)
WO (1) WO2001089584A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7383076B2 (en) * 2000-11-27 2008-06-03 The General Hospital Corporation Fluorescence-mediated molecular tomography
NO20015802D0 (en) * 2001-11-28 2001-11-28 Amersham Health As Diagnostic method
DE10222481A1 (en) * 2002-05-22 2003-12-04 Eucro Europe Contract Res Gmbh Contrast agent for use in imaging
US6961607B2 (en) 2002-07-31 2005-11-01 Uzgiris Egidijus E Method for assessing myocardial angiogenesis
GB0224799D0 (en) * 2002-10-25 2002-12-04 Amersham Plc Improved complex compositions
WO2004054623A1 (en) * 2002-12-16 2004-07-01 Amersham Health As Magnetic resonance imaging method and compounds for use in the method
WO2005004781A1 (en) * 2003-06-13 2005-01-20 Imarx Therapeutics, Inc. Non-invasive intravascular thrombolyisis using modified ultrasound techniques
GB0327494D0 (en) * 2003-11-26 2003-12-31 Amersham Plc Novel imaging agents
NO20035681D0 (en) * 2003-12-18 2003-12-18 Amersham Health As Optical imaging of lung cancer
NO20035682D0 (en) * 2003-12-18 2003-12-18 Amersham Health As Optical imaging of oesophageal cancer and Barrett's oesophagus
NO20035683D0 (en) * 2003-12-18 2003-12-18 Amersham Health As Optical imaging of prostate cancer
NO20035748D0 (en) * 2003-12-19 2003-12-19 Amersham Health As Optical imaging of vulnerable arteriosclerosis
US8052669B2 (en) 2004-02-25 2011-11-08 Femasys Inc. Methods and devices for delivery of compositions to conduits
US9238127B2 (en) 2004-02-25 2016-01-19 Femasys Inc. Methods and devices for delivering to conduit
US8048086B2 (en) 2004-02-25 2011-11-01 Femasys Inc. Methods and devices for conduit occlusion
US8048101B2 (en) * 2004-02-25 2011-11-01 Femasys Inc. Methods and devices for conduit occlusion
FI20040682A0 (en) * 2004-05-14 2004-05-14 Ctt Cancer Targeting Tech Oy Imaging of tumors and metastases using a peptide that has gelatinase
US20080095704A1 (en) * 2004-07-02 2008-04-24 Alan Cuthbertson Imaging Agents with Improved Pharmacokinetic Profiles
WO2007050319A1 (en) 2005-10-21 2007-05-03 Immunochemistry Technologies, Llc In vivo detection of apoptosis
EP1948248A2 (en) * 2005-11-06 2008-07-30 Katz-Brull, Rachel Magnetic resonance imaging and spectroscopy means and methods thereof
TW200806284A (en) * 2006-03-31 2008-02-01 Alcon Mfg Ltd Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
MX2010012473A (en) 2008-05-23 2011-02-23 Siwa Corp Methods, compositions and apparatuses for facilitating regeneration.
US10070888B2 (en) 2008-10-03 2018-09-11 Femasys, Inc. Methods and devices for sonographic imaging
US9554826B2 (en) 2008-10-03 2017-01-31 Femasys, Inc. Contrast agent injection system for sonographic imaging
US12171463B2 (en) 2008-10-03 2024-12-24 Femasys Inc. Contrast agent generation and injection system for sonographic imaging
EP2350013A4 (en) * 2008-10-13 2012-10-17 San Diego State University Res Foundation COMPOSITIONS FOR MARKING AND IDENTIFYING AUTOPHAGOSOMES AND METHOD FOR THE PRODUCTION AND USE THEREOF
AU2010230330B2 (en) * 2009-04-02 2015-06-25 Ge Healthcare Limited Use of a magnetic resonance imaging medium comprising hyperpolarized 13C pyruvate for the detection of inflammation or infection
DE102009054956A1 (en) * 2009-12-18 2011-06-22 Siemens Aktiengesellschaft, 80333 Magnetic resonance imaging
US9649376B2 (en) 2010-09-27 2017-05-16 Siwa Corporation Selective removal of age-modified cells for treatment of atherosclerosis
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
WO2013158230A1 (en) * 2012-04-19 2013-10-24 The Regents Of The University Of California Compositions and methods for detecting unstable arteriosclerotic plaques
ES2439167B1 (en) * 2012-06-21 2014-11-17 Consejo Superior De Investigaciones Científicas (Csic) Compounds with magnetic functionality, implants or gels derived from them, and the use of both to determine the enzymatic activity of an enzyme
CN107001459B (en) 2014-09-19 2021-11-23 Siwa有限公司 anti-AGE antibodies for the treatment of inflammatory and autoimmune disorders
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
PT3337829T (en) 2016-02-19 2020-02-10 Siwa Corp METHOD AND COMPOSITION FOR THE TREATMENT OF CANCER, KILLING METASTATIC CANCER CELLS AND PREVENTING CANCER METASTASES USING ANTIBODIES FOR FINAL PRODUCTS OF ADVANCED GLYCUS (PGA)
ES2932185T3 (en) * 2016-02-26 2023-01-16 Univ Southern California Optimized volumetric imaging with selective volume illumination and light field detection
WO2017156071A1 (en) 2016-03-09 2017-09-14 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
CA3057829A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
WO2017222535A1 (en) 2016-06-23 2017-12-28 Siwa Corporation Vaccines for use in treating various diseases and disorders
EP3481835A4 (en) 2016-07-05 2020-02-26 Blade Therapeutics, Inc. CALPAIN MODULATORS AND THEIR THERAPEUTIC USES
BR112019006110A2 (en) 2016-09-28 2019-09-10 Blade Therapeutics Inc calpain modulators and therapeutic uses thereof
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
CA3059803A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
AU2018289434A1 (en) * 2017-06-23 2020-01-16 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
WO2019136484A1 (en) * 2018-01-08 2019-07-11 Prevail Therapeutics, Inc. Pet imaging ligands for in vivo detection of gba1
CN120054360B (en) * 2025-03-10 2026-02-27 中国人民解放军军事科学院军事医学研究院 A method for generating hydrophilic monodisperse aerosols of different particle sizes for human inhalation

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4913891A (en) * 1986-04-17 1990-04-03 The United States Of America As Represented By The United States Department Of Energy Positron emitter labeled enzyme inhibitors
JPH0782285A (en) * 1993-09-10 1995-03-28 Eiken Chem Co Ltd Porphyrin / phosphate derivative
WO1997036619A2 (en) * 1996-04-01 1997-10-09 Epix Medical, Inc. Bioactivated diagnostic imaging contrast agents
DE19717904A1 (en) * 1997-04-23 1998-10-29 Diagnostikforschung Inst Acid-labile and enzymatically cleavable dye constructs for diagnostics with near infrared light and for therapy
CN1230438A (en) * 1998-03-27 1999-10-06 柯缨 Developer for supersonic diagnosis of oviduct and its use
WO1999058161A1 (en) * 1998-05-14 1999-11-18 The General Hospital Corporation Intramolecularly-quenched near infrared fluorescent probes
US6036941A (en) * 1995-07-19 2000-03-14 Consiglio Nazionale Delle Ricerche Fluorogenic substrates for diagnosis and photodynamic treatment of tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8522535D0 (en) * 1985-09-11 1985-10-16 Amersham Int Plc Contrast agent
US4874600A (en) * 1986-04-17 1989-10-17 The United States Of America As Represented By The United States Department Of Energy No-carrier-added [111 c]putrescine
US5204447A (en) * 1988-11-14 1993-04-20 Zymogenetics, Inc. Purification of factor xiii
US5792444A (en) * 1989-05-09 1998-08-11 The General Hospital Corporation Labeled chemotactic peptides to image focal sites of infection or inflammation
US5707605A (en) * 1995-06-02 1998-01-13 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
US5980862A (en) * 1995-06-02 1999-11-09 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
GB2348426B (en) * 1997-04-03 2001-06-27 California Inst Of Techn Enzyme-mediated modification of fibrin for tissue engineering

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4913891A (en) * 1986-04-17 1990-04-03 The United States Of America As Represented By The United States Department Of Energy Positron emitter labeled enzyme inhibitors
JPH0782285A (en) * 1993-09-10 1995-03-28 Eiken Chem Co Ltd Porphyrin / phosphate derivative
US6036941A (en) * 1995-07-19 2000-03-14 Consiglio Nazionale Delle Ricerche Fluorogenic substrates for diagnosis and photodynamic treatment of tumors
WO1997036619A2 (en) * 1996-04-01 1997-10-09 Epix Medical, Inc. Bioactivated diagnostic imaging contrast agents
DE19717904A1 (en) * 1997-04-23 1998-10-29 Diagnostikforschung Inst Acid-labile and enzymatically cleavable dye constructs for diagnostics with near infrared light and for therapy
CN1230438A (en) * 1998-03-27 1999-10-06 柯缨 Developer for supersonic diagnosis of oviduct and its use
WO1999058161A1 (en) * 1998-05-14 1999-11-18 The General Hospital Corporation Intramolecularly-quenched near infrared fluorescent probes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199521, Derwent World Patents Index; Class B02, AN 1995-158984, XP002902225 *
DATABASE WPI Section Ch Week 200011, Derwent World Patents Index; Class B04, AN 2000-117397, XP002902224 *

Also Published As

Publication number Publication date
EP1283728A2 (en) 2003-02-19
US20030170173A1 (en) 2003-09-11
WO2001089584A2 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
WO2001089584A3 (en) Contrast agents
WO2002040634A3 (en) Expression miniarrays and uses thereof
WO2005027733A3 (en) Biological markers for diagnosing multiple sclerosis
WO2006089233A3 (en) Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
WO2004011611A3 (en) Taci antibodies and uses thereof
EP2478877A3 (en) Urine sensor
WO2005100602A3 (en) Biosensor based on directed assembly of particles
WO2002039086A8 (en) Glucose sensor system
WO2003066661A3 (en) Human dr4 antibodies and uses thereof
WO2002086448A3 (en) Detection of microsatellite instability and its use in diagnosis of tumors
WO2000070945A3 (en) Fatty acid elongation genes and uses thereof
WO2000070340A3 (en) Materials and methods relating to disease diagnosis
WO2003016563A3 (en) Novel molecular target for neurotoxicity
AU2002330215A1 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
WO2001066721A3 (en) Nucleic acid sensor molecules
WO2003085082A3 (en) Nucleic acid reactions using labels with different redox potentials
WO2003093429A3 (en) Nucleic acid reactions using labels with different redox potentials
WO2002059611A3 (en) Diagnosis and treatment of cancer using mammalian pellino polypeptides and polynucleotides
WO2002070741A3 (en) Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna
WO2001077305A3 (en) Variants of the human amp-activated protein kinase gamma 3 subunit
WO2004027062A3 (en) Functional correction of the -786c/t variance of the human enos gene
WO2002029099A1 (en) Method of screening physiologically active substance
WO2000058509A3 (en) Prostate cancer associated human fibronectin gene and biallelic markers
PT1328289E (en) Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof
AU2003218601A1 (en) Phox2b polymorphisms as hirschsprung's disease diagnostic markers and methods based thereon

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10302419

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001941323

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001941323

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001941323

Country of ref document: EP